Results 101 to 110 of about 2,608,192 (371)

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Lymphangiogenesis requires Ang2/Tie/PI3K signaling for VEGFR3 cell-surface expression

The Journal of Clinical Investigation, 2022
Vascular endothelial growth factor C (VEGF-C) induces lymphangiogenesis via VEGF receptor 3 (VEGFR3), which is encoded by the most frequently mutated gene in human primary lymphedema. Angiopoietins (Angs) and their Tie receptors regulate lymphatic vessel
Emilia A. Korhonen, Aino Murtomäki, Sawan Kumar Jha, Andrey Anisimov, Anne Pink, Yan Zhang, Simon Stritt, Inam Liaqat, Lukas Stanczuk, Laura Alderfer, Zhiliang Sun, Emmi Kapiainen, Abhishek Singh, Ibrahim Sultan, Anni Lantta, Veli-Matti Leppänen, Lauri Eklund, Yulong He, Hellmut G. Augustin, Kari Vaahtomeri, Pipsa Saharinen, Taija Mäkinen, Kari Alitalo   +22 more
doaj   +1 more source

Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB

Acta Neuropathologica, 2008
Members of the vascular endothelial growth factor (VEGF) family are key signaling proteins in the induction and regulation of angiogenesis, both during development and in pathological conditions.
K. Boer, D. Troost, W. Spliet, P. V. van Rijen, J. Gorter, E. Aronica   +5 more
semanticscholar   +1 more source

PDGFB as a vascular normalization agent in an ovarian cancer model treated with a gamma-secretase inhibitor [PDF]

, 2019
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. In the past 20 years, the canonical types of drugs used to treat ovarian cancer have not been replaced and the survival rates have not changed.
Abramovich, Dalhia Nurit, Bocchicchio, Sebastian, Irusta, Griselda, May, Maria, Parborell, Maria Fernanda Agustina, Pazos Maidana, María Camila, Sequeira, Gonzalo Ricardo, Tesone, Marta   +7 more
core   +1 more source

LIN28B Promotes Cancer Cell Dissemination and Angiogenesis

Advanced Biology, EarlyView.
Children diagnosed with high‐risk neuroblastoma have a 5‐year event‐free survival rate of less than 50% and poor outcomes after recurrence. Deregulation of the LIN28B oncogene can be addressed in these patients. Upregulation of LIN28B is shown to support the metastatic cascade.
Diana Corallo, Sara Menegazzo, Marcella Pantile, Silvia Bresolin, Carlo Zanon, Alessandro Davini, Massimiliano Mazzone, Alessandra Biffi, Sanja Aveic   +8 more
wiley   +1 more source

RET mutation and increased angiogenesis in medullary thyroid carcinomas [PDF]

, 2016
Advanced medullary thyroid cancers (MTCs) are now being treated with drugs that inhibit receptor tyrosine kinases, many of which involved in angiogenesis.
Acquaviva, Giorgia, Boichard, Amélie, Casadei, Gian Piero, Checquolo, Saula, Colato, Chiara, de Biase, Dario, Durante, Cosimo, Ferdeghini, Marco, Filetti, Sebastiano, Pecce, Valeria, Rhoden, Kerry, Rosignolo, Francesca, Russo, Diego, Sponziello, Marialuisa, Tallini, Giovanni, Verrienti, Antonella, Visani, Michela   +16 more
core   +1 more source

Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment

Advanced Biology, EarlyView.
The prodrug strategy used in this study offers new promise for cancer metabolism‐based therapies. JHU083, a prodrug that, when cleaved by protease in the tumor microenvironment, yields the glutamine antagonist DON. JHU083 inhibits tumor growth by targeting glutamine‐addicted cancer cells and suppressing glutamine‐dependent M2 macrophages, leading to a ...
Tianhe Li, Sepehr Akhtarkhavari, Sumeng Qi, Jiawei Fan, Tu‐Yung Chang, Yao‐An Shen, JinMing Yang, Barbara S. Slusher, Ie‐Ming Shih, Stephanie Gaillard, Tian‐Li Wang   +10 more
wiley   +1 more source

Role of the Angiogenic Factors in Cholangiocarcinoma

Applied Sciences, 2019
Angiogenesis plays a fundamental role in tumor growth and progression. It is regulated by several growth factors, including vascular endothelial growth factor protein family (VEGF) and its receptors, which are probably the most important factors ...
Romina Mancinelli, Caterina Loredana Mammola, Roberta Sferra, Simona Pompili, Antonella Vetuschi, Luigi Pannarale   +5 more
doaj   +1 more source

Downregulation of genes with a function in axon outgrowth and synapse formation in motor neurones of the VEGF(delta/delta) mouse model of amyotrophic lateral sclerosis [PDF]

, 2010
Background: Vascular endothelial growth factor (VEGF) is an endothelial cell mitogen that stimulates vasculogenesis. It has also been shown to act as a neurotrophic factor in vitro and in vivo.
Bender, F.L.P., Brockington, A., Carmeliet, P., Claes, F., Heath, P.R., Holden, H., Kasher, P., Lambrechts, D., Sendtner, M., Shaw, P.J.   +9 more
core   +4 more sources

KDR (VEGF Receptor 2) Is the Major Mediator for the Hypotensive Effect of VEGF [PDF]

Hypertension, 2002
Vascular endothelial growth factor (VEGF) exerts vasodilation-induced hypotension as a major side effect for treatment of ischemic diseases. VEGF has 2 receptor tyrosine kinases, KDR and Flt-1. Little is known about which receptor mediates VEGF-induced hypotension.
Bing Li, Abraham M. de Vos, Annie K. Ogasawara, Hongkui Jin, Thomas F. Zioncheck, Stuart Bunting, Renhui Yang, Guo-Wei He, Wei Wei   +8 more
openaire   +3 more sources